| abstract |
The present disclosure relates to compounds that bind to an IAP BIR domain, more specifically, a BIR2 domain and a BITR3 domain. The compound is represented by Formula 1: (I). These compounds have been found to be useful in altering the apoptotic response in cells and may lead to the treatment of proliferative diseases. The apoptotic pathway is known to play an important role in the development of cancer, autoimmune diseases, and neurodegenerative diseases. A method for producing the compound of Formula 1 is also disclosed. |